Juvmo (tavapadon)

Name: Juvmo (tavapadon) in Parkinson's disease: Model outcomes
Published: 2026-09-27T21:44:59-04:00

Parkinson's disease

Also known as CVL-751

Manufacturer: AbbVie
Regulatory submission: NDA submitted September 2025
Launch: Expected by Citi analysts in the third quarter of 2026
Last updated: October 1, 2026

Section

Economic information and modeling report Budget impact model

Model outcomes

1 evidence topic · 1 source

ICER potential budget impact analysis: outcome measures and threshold

“Figure 7.1 illustrates the cumulative per-patient potential budget impact of tavapadon as first-line treatment compared with levodopa over the five-year time horizon, assuming 20% uptake each year.” (opens the source at this quote in a new tab)
“For 2025–2026, the five-year annualized potential budget impact threshold that should trigger policy actions to manage access and affordability is approximately $821 million per year for new drugs.” (opens the source at this quote in a new tab)